Since LV failure could lead to pulmonary inflammation, remodeling, and RV hypertrophy, the reduced lung inflammation, remodeling, and RV hypertrophy in anti-IL12β antibody-treated mice after TAC could be due to both the improved cardiac function in these mice and the reduced lung inflammation. The gene discussed is IL12B; the disease is persistent truncus arteriosus.